Latest Cynapsus Therapeutic (CYNAF) Headlines Cynapsus

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Cynapsus Therapeutic (CYNAF) Headlines

Cynapsus Therapeutics Announces DTC Approval
Marketwire - Thu Feb 27, 8:24AM CST
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that the common shares of the Company (CUSIP 23257Y701) have been made eligible for book-entry delivery and depository services of The Depository Trust Company (the "DTC") to facilitate electronic settlement of transfers of its common shares in the United States.

Cynapsus Therapeutics Appoints Nan Hutchinson to the Board of Directors
Marketwire - Thu Feb 13, 7:02AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company with a lead program in Parkinson's disease, today announced the appointment of Nan Hutchinson to the Board of Directors.

LifeSci Advisors Initiates Coverage of Cynapsus Therapeutics, Inc.
Marketwire - Fri Feb 07, 8:15AM CST
LifeSci Advisors, LLC announcement for Cynapsus Therapeutics, Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF)

Cynapsus Therapeutics Announces Exercise of Warrants
Marketwire - Thu Jan 23, 3:01PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that in January, 125,324 warrants with an exercise price of $0.575 have been exercised for total proceeds of $72,062. Following the exercise of these warrants, Cynapsus has 39,009,335 commons shares, 21,426,439 warrants and 2,691,316 options to purchase common shares outstanding.

Cynapsus Announces Resignation of Chief Scientific Officer
Marketwire - Wed Jan 22, 3:31PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that Nathan Bryson, Chief Scientific Officer, will be leaving the Company to pursue other opportunities.

Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277
Marketwire - Mon Jan 13, 5:01AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive top line data from its recently completed healthy volunteer pilot crossover trial comparing APL-130277, a sublingual thin film strip formulation of apomorphine, to a commercially available injectable formulation of apomorphine. The study results further support the advancement of APL-130277 for management of "OFF" episodes in Parkinson's disease through the section 505(b)(2) regulations of the United States Food and Drug Administration Act, which provides an accelerated path to approval for new formulations of approved medicines.

SeeThruEquity, LLC Initiates Coverage on Cynapsus Therapeutics Inc.
Marketwire - Tue Nov 26, 8:03AM CST
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that SeeThruEquity, LLC, an independent investment research and corporate access firm, has initiated equity research coverage on the Company. The research report is available for viewing and downloading at www.seethruequity.com.

Cynapsus Therapeutics Reports Third Quarter 2013 Financial Results and Recent Developments
Marketwire - Thu Nov 21, 3:43PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of "off" motor symptoms of Parkinson's disease, today announced its results for the nine months ended September 30, 2013. Unless specified otherwise, all amounts are in Canadian dollars.

Cynapsus Therapeutics Reports Second Quarter 2013 Financial Results and Recent Developments
Marketwire - Thu Aug 22, 3:18PM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing the only oral (sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease, today announced its results for the six months ended June 30, 2013. Unless specified otherwise, all amounts are in Canadian dollars.

Cynapsus Therapeutics Is First to Develop Convenient Delivery of Apomorphine for Parkinson's Patients Experiencing "OFF" Episodes, Says Zacks Analyst via Interview With the Life Sciences Report
Marketwire - Mon Aug 05, 8:37AM CDT
Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in an interview with George Mack of The Life Sciences Report, "Cynapsus Therapeutics Inc. (OTCQX: CYNAF) (TSX VENTURE: CTH) is a small Canadian company developing a sublingual formulation of a drug called apomorphine, which is a rescue medication for Parkinson's disease patients who experience something called 'off time,' a rigid or frozen state that occurs when their levodopa + carbidopa medication has worn off. This typically happens in the morning, because the Parkinson's patient takes his or her last dose of medication before bed, and it has worn off by the time they awaken. Apomorphine is a rapid rescue medication for that "off time" state. Cynapsus' sublingual film formulation of apomorphine is put under the tongue and dissolves in a very short period of time. Patients with dyskinesia can take it themselves. It just makes sense.

Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Begins Trading on the OTCQX Marketplace in the United States
Marketwire - Thu Jul 18, 6:07AM CDT
July 18, 2013

Cynapsus Therapeutics Inc. (CYNA) Stock Research Links

CYNA Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NOAA Taps ICEYE US for Game-Changing SAR Satellite Data

Updated Category News Views 6

The Strategic Move to SAR Data Imagine this: You’re in the thick of a hurricane, where visibility goes out the window, and traditional satellite data chokes under the crushing weight of clouds and nightfall. That's the precise chaos ICEYE US is cutting through with its Synthetic Aperture Radar (SAR) technology. The latest scuttlebutt is that NOAA's getting cozy with...

Continue Reading
WellLink Advisory Board Eyes Future of Healthcare Innovation

Updated Category News Views 3

Strategic Collaboration for Healthcare Evolution Ready to shake things up in healthcare, WellLink is setting the stage with its brand new Advisory Board. This move isn’t just about having fancy titles sitting around a conference table — it's about grabbing onto the future with both hands and figuring out just what the heck the healthcare industry needs next....

Continue Reading
TGI Fridays Unveils New 3 For All Menu Options

Updated Category News Views 7

Hedging Bets on New Dining Strategies Oh, the restaurant battlefield—where one day you're the toast of the town, and the next, you're hustling to keep those seats filled. TGI Fridays, a name as synonymous with casual eats as long as I’ve been in this game, is rolling the dice with a new offering dubbed '3 For All.' Doesn't sound like your average meal deal either....

Continue Reading
Lumicell Expands LumiSystem in Breast Cancer Surgery

Updated Category News Views 6

Innovation in Breast Cancer Surgery: A Real-World Game Changer? You’ve got your flashlight guiding a scared child through the dark, and in the healthcare world, Lumicell is promising to do just that for surgeons navigating the tricky maze of breast cancer surgery. Their LumiSystem is making waves in breast-conserving surgery—new kid on the block with a real chance at...

Continue Reading
RxWellness Hits Inc. 5000—Four Straight Wins Impress

Updated Category News Views 6

RxWellness Spine & Health Continues to Impress Well, not many companies can boast about snagging a spot on the Inc. 5000 list four years in a row, but here we are with RxWellness Spine & Health doing just that. Sitting pretty at No. 1,230 nationally—and that's no small feat—these folks are making waves in the healthcare industry. Securing the No. 135 spot in...

Continue Reading
Perk's U.S. Expansion: A Bold Move in Spend Control

Updated Category News Views 5

Perk Aims for U.S. Growth: Will It Pay Off? Amidst the cacophony of market chatter, Perk's announcement to bring its spend platform stateside is echoing louder than usual. This move is not just another step in its expansion but rather a leap considering the competition and market needs. In Europe, where they've already captured a chunk of the market with their Travel and...

Continue Reading
CSS Revamps Identity, Emphasizing Senior Living Tech

Updated Category News Views 4

CSS Takes a Bold Step with a Fresh Brand Identity Every now and then, you see a company shake off the old coat and put on a polished new one. That's what CSS is doing with its updated brand, staking its claim as a heavyweight tech player in the senior living sector. No small feat, given the challenges stacked against these aging communities—tasked with keeping...

Continue Reading
Avive Partners with Cambridge Fire for Lifesaving Training

Updated Category News Views 5

Tapping into the Pulse: Avive & Cambridge Fire in Action No fooling around here—Avive Solutions is linking arms with the Cambridge Fire Department to put the city on a faster track to becoming a lifesaver haven. They're rolling out a free CPR and AED training right in the Smith Campus Center, Harvard Square. It's the kind of thing you love to see—getting the community...

Continue Reading
Alcott HR's Sales Strategy Gets a Boost with New Hire

Updated Category News Views 9

Alcott HR Ramps Up Sales Firepower Now here's something fresh from the world of human resources outsourcing—Alcott HR has grabbed a new ace for their sales team. Eldin Radoncic is the name you'll want to remember, folks, because he's diving headfirst into the Director of Sales seat at this IRS Certified and ESAC Accredited player based out in good old Farmingdale, New...

Continue Reading
Orthopedic Expert Highlighting Midwest Pain Access Gaps

Updated Category News Views 5

Over in the vast sprawl of rolling plains and prairie winds, folks in the Upper Midwest are grappling with an ironic reality. As technological advancements blaze trails, people suffering from vertebrogenic pain are finding themselves up against a wall of limited access to specialized care. We’ve got Dr. James T. Brunz, the man of the hour, one of only about 15 Intracept...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for Shareholders of Joint Stock Company Kaspi.kz

Updated Category News Views 137

Latest Developments for Shareholders of Kaspi.kz Shareholders of Joint Stock Company Kaspi.kz (NASDAQ: KSPI) are urged to be proactive regarding their rights and potential claims stemming from recent allegations against the company. The Gross Law Firm is reaching out to those who purchased shares during the specified class period, providing essential information on how to...

Continue Reading
Transform Your Faith by Exploring Biblical Teachings and Insights

Updated Category News Views 169

Embrace a Deeper Christian Faith Through New Book An intriguing new release seeks to guide individuals on their spiritual journey. The author, who transformed his life through a commitment to God, shares profound insights gained from extensive exploration of the Holy Bible. This carefully crafted book dives into six essential biblical themes, providing readers with a...

Continue Reading
Miami's Global Appeal: New Construction Units in High Demand

Updated Category News Views 204

Rising Global Interest in Miami’s New Construction Market Miami has become a hotspot for international buyers, with residents from 73 different countries increasingly investing in the city’s new construction units. A recent report shows that global buyers purchased 52% of all new South Florida construction, which encompasses pre-construction and condo conversions over...

Continue Reading
Important Information for NNE Investors Before Class Action

Updated Category News Views 120

Understanding the Class Action for NANO Nuclear Energy, Inc. In the fast-paced investment world, news can change everything. This is especially true for shareholders of NANO Nuclear Energy, Inc. (NASDAQ: NNE). If you own shares in this company, it’s crucial to be aware of important developments, particularly regarding the upcoming class action lawsuit. Why This Matters...

Continue Reading
Anticipated Federal Reserve Interest Rate Cuts and Insights

Updated Category News Views 104

Federal Reserve's Expected Action on Interest Rates The Federal Reserve is on the brink of enacting a 25-basis point interest rate cut, a move anticipated at the conclusion of a recent two-day policy meeting. Implications of Recent Job Reports The latest jobs report has all but confirmed the market's expectations for a smaller rate adjustment. In recent months, job growth...

Continue Reading